



< Back to results | 1 of 30 Next >

Download Print E-mail Save to PDF Add to List More... >

Full Text

Journal of Computational Biophysics and Chemistry • 2022

Document type

Article

Source type

Journal

ISSN

27374165

DOI

10.1142/S2737416523500059

Publisher

World Scientific

Original language

English

View less ^

Identification of Novel 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors by an Integrated Method of Pharmacophore Virtual Screening, Docking, QSAR and ADMET Analyses

Rullah, Kamal^a ; Roney, Miah^b; Ibrahim, Zalikha^a; Shamsudin, Nur Farisya^a; Islami, Deri^c;

Ahmed, Qamar Uddin^a; Wai, Lam Kok^d; Aluwi, Mohd Fadhlizil Fasihi Mohd^b

Save all to author list

^a Drug Discovery And Synthetic Chemistry Research Group, Department Of Pharmaceutical Chemistry, Kulliyyah Of Pharmacy, International Islamic University Malaysia, Bandar Indera Mahkota, Kuantan, Pahang, 25200, Malaysia

^b Faculty Of Industrial Sciences & Technology, Universiti Malaysia Pahang, Lebuhraya Tun Razak, Gambang, Pahang, 26300, Malaysia

^c Faculty Of Pharmacy And Health Sciences, Universitas Abdurrab, Jalan Riau Ujung, Pekanbaru, Riau, 28292, Indonesia

^d Drugs And Herbal Research Centre, Faculty Of Pharmacy, Universiti Kebangsaan Malaysia, Jalan Raja Muda Abdul Aziz, Kuala Lumpur, 50300, Malaysia

Full text options Export

Abstract

Author keywords

Metrics

Abstract

This study explored a series of reported 5-lipoxygenase-activating protein (FLAP) inhibitors to understand their structural requirements and identify potential new inhibitor scaffolds through automated unbiased procedures. Docking studies have revealed that inhibitor binding affinity can be influenced by several key binding interactions with Phe114 and Lys116 from chain B and Val21, Phe25, His28 and Lys29 from chain C in the FLAP-binding site. A ligand-based alignment three-dimensional

Cited by 0 documents

Inform me when this document is cited in Scopus:

Set citation alert >

Related documents

Discovery of Novel 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors by Exploiting a Multistep Virtual Screening Protocol

Olgac, A. , Carotti, A. , Kretzer, C. (2020) *Journal of Chemical Information and Modeling*

Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease

Pettersen, D. , Broddefalk, J. , Emtenas, H. (2019) *Journal of Medicinal Chemistry*

A single amino acid difference between mouse and human 5-lipoxygenase activating protein (FLAP) explains the speciation and differential pharmacology of novel FLAP inhibitors

Blevitt, J.M. , Hack, M.D. , Herman, K. (2016) *Journal of Biological Chemistry*

View all related documents based on references

Find more related documents in Scopus based on:

Authors > Keywords >

(3D)-quantitative structure-activity relationship (QSAR) was adopted, resulting in a robust model with a statistically significant noncross-validated coefficient ($r^2=0.992$), a cross-validated correlation coefficient ($q^2=0.681$) and a predictive squared correlation coefficient ($r_{pred}^2=0.736$). Overall, the analysis revealed the important electrostatic and steric attributes responsible for the FLAP inhibitory activity, which appeared to correlate well with the docking results. In addition, two statistically significant two-dimensional (2D)-QSAR models ($r^2=0.9369$, $q^2=0.889$ and $r^2=0.9679$, $q^2=0.655$) were developed by a genetic function approximation (GFA). HypoGen 1, a proposed pharmacophore model, was used for database mining to identify potential new FLAP inhibitors. The bioactivity of the retrieved hits was then evaluated in silico based on the validated QSAR models, followed by pharmacokinetics and toxicity predictions. © 2022 World Scientific Publishing Company.

Author keywords

2D- and 3D-QSAR; 5-lipoxygenase-activating protein (FLAP); Docking; inflammation; pharmacophore; virtual screening

Metrics 

References (38)

[View in search results format >](#)

All

[Export](#)  [Print](#)  [E-mail](#)  [Save to PDF](#) [Create bibliography](#)

- 1 Jo-Watanabe, A., Okuno, T., Yokomizo, T.
The role of leukotrienes as potential therapeutic targets in allergic disorders ([Open Access](#))

(2019) *International Journal of Molecular Sciences*, 20 (14), art. no. 3580. Cited 55 times.

<https://www.mdpi.com/1422-0067/20/14/3580/pdf>
doi: 10.3390/ijms20143580

[View at Publisher](#)

- 2 Peters-Golden, M., Brock, T.G.
5-Lipoxygenase and FLAP

(2003) *Prostaglandins Leukotrienes and Essential Fatty Acids*, 69 (2-3), pp. 99-109. Cited 168 times.

<http://www.elsevier-international.com/journals/plef/>
doi: 10.1016/S0952-3278(03)00070-X

[View at Publisher](#)

- 3 Vickers, P.J.
5-Lipoxygenase-activating protein (FLAP)

(1995) *Journal of Lipid Mediators and Cell Signalling*, 12 (2-3), pp. 185-194. Cited 58 times.

doi: 10.1016/0929-7855(95)00018-L

[View at Publisher](#)

- 4 Evans, J.F., Ferguson, A.D., Mosley, R.T., Hutchinson, J.H.
What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases

(2008) *Trends in Pharmacological Sciences*, 29 (2), pp. 72-78. Cited 188 times.
doi: 10.1016/j.tips.2007.11.006

[View at Publisher](#)

- 5 Ferguson, A.D., McKeever, B.M., Xu, S., Wisniewski, D., Miller, D.K., Yamin, T.-T., Spencer, R.H., (...), Becker, J.W.

Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein

(2007) *Science*, 317 (5837), pp. 510-512. Cited 185 times.
doi: 10.1126/science.1144346

[View at Publisher](#)

- 6 Colazzo, F., Gelosa, P., Tremoli, E., Sironi, L., Castiglioni, L.

Role of the Cysteinyl Leukotrienes in the Pathogenesis and Progression of Cardiovascular Diseases ([Open Access](#))

(2017) *Mediators of Inflammation*, 2017, art. no. 2432958. Cited 46 times.
<http://www.hindawi.com/journals/mi/>
doi: 10.1155/2017/2432958

[View at Publisher](#)

- 7 Gilbert, N.C., Bartlett, S.G., Waight, M.T., Neau, D.B., Boeglin, W.E., Brash, A.R., Newcomer, M.E.

The structure of human 5-lipoxygenase ([Open Access](#))

(2011) *Science*, 331 (6014), pp. 217-219. Cited 312 times.
<http://www.sciencemag.org/content/331/6014/217.full.pdf>
doi: 10.1126/science.1197203

[View at Publisher](#)

- 8 Pettersen, D., Davidsson, Ö., Whatling, C.

Recent advances for FLAP inhibitors

(2015) *Bioorganic and Medicinal Chemistry Letters*, 25 (13), pp. 2607-2612. Cited 31 times.
<http://www.journals.elsevier.com/bioorganic-and-medicinal-chemistry-letters/>
doi: 10.1016/j.bmcl.2015.04.090

[View at Publisher](#)

- 9 Prasit, P., Belley, M., Blouin, M., Brideau, C., Chan, C., Charleson, S., Evans, J.F., (...), McFarlane, C.S.

A new class of leukotriene biosynthesis inhibitor: The development of MK-0591

(1992) *Journal of Lipid Mediators*, 6 (1-3), pp. 239-244. Cited 30 times.

- 10 Stock, N., Baccei, C., Bain, G., Chapman, C., Correa, L., Darlington, J., King, C., (...), Prasit, P.

5-Lipoxygenase-activating protein inhibitors. Part 3: 3-{3-tert-Butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-5-(5-methyl-pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM643) - A potent FLAP inhibitor suitable for topical administration

(2010) *Bioorganic and Medicinal Chemistry Letters*, 20 (15), pp. 4598-4601. Cited 14 times.
doi: 10.1016/j.bmcl.2010.06.011

[View at Publisher](#)

- 11 Lin, C., Hsieh, J.Y.-K., Matuszewski, B.K., Dobrinska, M.R.
An automated sample preparation and high performance liquid chromatographic method for the determination of MK-591, a novel leukotriene biosynthesis inhibitor, in human plasma
(1996) *Journal of Pharmaceutical and Biomedical Analysis*, 14 (11), pp. 1601-1608. Cited 7 times.
www.elsevier.com/locate/jpba
doi: 10.1016/0731-7085(96)01737-2
View at Publisher
-
- 12 Diamant, Z., Timmersa, M.C., van der Veena, H., Friedman, B.S., Smet, M.D., Depré, M., Hilliard, D., (...), Sterk, P.J.
The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo
(1995) *The Journal of Allergy and Clinical Immunology*, 95 (1-2), pp. 42-51. Cited 145 times.
doi: 10.1016/S0091-6749(95)70151-6
View at Publisher
-
- 13 Koeberle, A., Siemoneit, U., Northoff, H., Hofmann, B., Schneider, G., Werz, O.
MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation
(2009) *European Journal of Pharmacology*, 608 (1-3), pp. 84-90. Cited 22 times.
doi: 10.1016/j.ejphar.2009.02.023
View at Publisher
-
- 14 Lorrain, D.S., Bain, G., Correa, L.D., Chapman, C., Broadhead, A.R., Santini, A.M., Prodanovich, P.P., (...), Evans, J.F.
Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation
(2010) *European Journal of Pharmacology*, 640 (1-3), pp. 211-218. Cited 22 times.
doi: 10.1016/j.ejphar.2010.05.003
View at Publisher
-
- 15 Harris, R.R., Carter, G.W., Bell, R.L., Moore, J.L., Brooks, D.W.
Clinical activity of leukotriene inhibitors
(1995) *International Journal of Immunopharmacology*, 17 (2), pp. 147-156. Cited 56 times.
doi: 10.1016/0192-0561(94)00093-4
View at Publisher
-
- 16 Gür, Z.T., Çalışkan, B., Banoglu, E.
Drug discovery approaches targeting 5-lipoxygenase-activating protein (FLAP) for inhibition of cellular leukotriene biosynthesis
(2018) *European Journal of Medicinal Chemistry*, 153, pp. 34-48. Cited 35 times.
<http://www.journals.elsevier.com/european-journal-of-medicinal-chemistry/>
doi: 10.1016/j.ejmech.2017.07.019
View at Publisher

- 17 Pettersen, D., Broddefalk, J., Emtenäs, H., Hayes, M.A., Lemurell, M., Swanson, M., Ulander, J., (...), Lindstedt, E.-L.
Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease
(2019) *Journal of Medicinal Chemistry*, 62 (9), pp. 4312-4324. Cited 22 times.
<http://pubs.acs.org/jmc>
doi: 10.1021/acs.jmedchem.8b02004
View at Publisher
-
- 18 Garscha, U., Romp, E., Pace, S., Rossi, A., Temml, V., Schuster, D., König, S., (...), Werz, O.
Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase (Open Access)
(2017) *Scientific Reports*, 7 (1), art. no. 9398. Cited 29 times.
www.nature.com/srep/index.html
doi: 10.1038/s41598-017-09795-w
View at Publisher
-
- 19 Wu, F., Zhou, Y., Li, L., Shen, X., Chen, G., Wang, X., Liang, X., (...), Huang, Z.
Computational Approaches in Preclinical Studies on Drug Discovery and Development (Open Access)
(2020) *Frontiers in Chemistry*, 8, art. no. 726. Cited 58 times.
<http://journal.frontiersin.org/journal/chemistry>
doi: 10.3389/fchem.2020.00726
View at Publisher
-
- 20 Polishchuk, P.
Interpretation of Quantitative Structure-Activity Relationship Models: Past, Present, and Future
(2017) *Journal of Chemical Information and Modeling*, 57 (11), pp. 2618-2639. Cited 109 times.
<http://pubs.acs.org/journal/jcisd8>
doi: 10.1021/acs.jcim.7b00274
View at Publisher
-
- 21 Fasihi Mohd Aluwi, M.F., Rullah, K., Koeberle, A., Werz, O., Abdul Razak, N.S., Wei, L.S., Salim, F., (...), Wai, L.K.
Design and synthesis of a novel mPGES-1 lead inhibitor guided by 3D-QSAR CoMFA (Open Access)
(2019) *Journal of Molecular Structure*, 1196, pp. 844-850. Cited 5 times.
<https://www.journals.elsevier.com/journal-of-molecular-structure>
doi: 10.1016/j.molstruc.2019.07.004
View at Publisher
-
- 22 Rogers, D., Hopfinger, A.J.
Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships
(1994) *Journal of Chemical Information and Computer Sciences*, 34 (4), pp. 854-866. Cited 983 times.
doi: 10.1021/ci00020a020
View at Publisher

- 23 Rullah, K., Mohd Aluwi, M.F.F., Yamin, B.M., Baharuddin, M.S., Ismail, N.H., Teruna, H.Y., Bukhari, S.N.A., (...), Wai, L.K.
Molecular characterization, biological activity, and in silico study of 2-(3,4-dimethoxyphenyl)-3-(4-fluorophenyl)-6-methoxy-4H-chromen-4-one as a novel selective COX-2 inhibitor
(2015) *Journal of Molecular Structure*, 1081, pp. 51-61. Cited 11 times.
www.elsevier.com/inca/publications/store/5/0/0/8/5/0/index.htm
doi: 10.1016/j.molstruc.2014.10.004
View at Publisher
-
- 24 Ferguson, A.D., McKeever, B.M., Xu, S., Wisniewski, D., Miller, D.K., Yamin, T.-T., Spencer, R.H., (...), Becker, J.W.
Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein
(2007) *Science*, 317 (5837), pp. 510-512. Cited 185 times.
doi: 10.1126/science.1144346
View at Publisher
-
- 25 Stock, N., Baccei, C., Bain, G., Broadhead, A., Chapman, C., Darlington, J., King, C., (...), Prasit, P.
5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)-A potent FLAP inhibitor
(2010) *Bioorganic and Medicinal Chemistry Letters*, 20 (1), pp. 213-217. Cited 23 times.
doi: 10.1016/j.bmcl.2009.10.131
View at Publisher
-
- 26 Ramírez, D., Caballero, J.
Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data? (Open Access)
(2018) *Molecules*, 23 (5), art. no. 1038. Cited 155 times.
<http://www.mdpi.com/1420-3049/23/5/1038/pdf>
doi: 10.3390/molecules23051038
View at Publisher
-
- 27 Banoglu, E., Çalişkan, B., Luderer, S., Eren, G., Özkan, Y., Altenhofen, W., Weinigel, C., (...), Werz, O.
Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase-activating protein (FLAP)
(2012) *Bioorganic and Medicinal Chemistry*, 20 (12), pp. 3728-3741. Cited 43 times.
doi: 10.1016/j.bmc.2012.04.048
View at Publisher
-
- 28 Vickers, P.J.
5-Lipoxygenase-activating protein (FLAP)
(1995) *Journal of Lipid Mediators and Cell Signalling*, 12 (2-3), pp. 185-194. Cited 58 times.
doi: 10.1016/0929-7855(95)00018-L
View at Publisher

- 29 Banoglu, E., Çelikoğlu, E., Völker, S., Olgaç, A., Gerstmeier, J., Garscha, U., Çalişkan, B., (...), Werz, O.
4,5-Diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP)
(2016) *European Journal of Medicinal Chemistry*, 113, pp. 1-10. Cited 34 times.
<http://www.journals.elsevier.com/european-journal-of-medicinal-chemistry/>
doi: 10.1016/j.ejmech.2016.02.027
View at Publisher
-
- 30 Hutchinson, J.H., Li, Y., Arruda, J.M., Baccei, C., Bain, G., Chapman, C., Correa, L., (...), Evans, J.F.
5-Lipoxygenase-activating protein inhibitors: Development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103)
(2009) *Journal of Medicinal Chemistry*, 52 (19), pp. 5803-5815. Cited 40 times.
<http://pubs.acs.org/doi/pdfplus/10.1021/jm900945d>
doi: 10.1021/jm900945d
View at Publisher
-
- 31 Rogers, D., Hahn, M.
Extended-connectivity fingerprints
(2010) *Journal of Chemical Information and Modeling*, 50 (5), pp. 742-754. Cited 3029 times.
<http://pubs.acs.org/journal/jcisd8>
doi: 10.1021/ci100050t
View at Publisher
-
- 32 Leeson, P.
Drug discovery: Chemical beauty contest
(2012) *Nature*, 481 (7382), pp. 455-456. Cited 206 times.
doi: 10.1038/481455a
View at Publisher
-
- 33 Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J.
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
(1997) *Advanced Drug Delivery Reviews*, 23 (1-3), pp. 3-25. Cited 8212 times.
doi: 10.1016/S0169-409X(96)00423-1
View at Publisher
-
- 34 Li, Z.-G., Chen, K.-X., Xie, H.-Y., Gao, J.-R.
Quantitative structure - Activity relationship analysis of some thiourea derivatives with activities against HIV-1 (IIIB)
(2009) *QSAR and Combinatorial Science*, 28 (1), pp. 89-97. Cited 10 times.
<http://www3.interscience.wiley.com/cgi-bin/fulltext/121502262/PDFSTART>
doi: 10.1002/qsar.200860097
View at Publisher
-

- 35 Wang, Z., Sun, H., Shen, C., Hu, X., Gao, J., Li, D., Cao, D., (...), Hou, T.
Combined strategies in structure-based virtual screening
(2020) *Physical Chemistry Chemical Physics*, 22 (6), pp. 3149-3159. Cited 55 times.
<http://pubs.rsc.org/en/journals/journal/cp>
doi: 10.1039/c9cp06303j
View at Publisher

- 36 Zhuang, C., Zhang, W., Sheng, C., Zhang, W., Xing, C., Miao, Z.
Chalcone: A Privileged Structure in Medicinal Chemistry
(Open Access)
(2017) *Chemical Reviews*, 117 (12), pp. 7762-7810. Cited 701 times.
<http://pubs.acs.org/journal/chreay>
doi: 10.1021/acs.chemrev.7b00020
View at Publisher

- 37 Rammohan, A., Reddy, J.S., Sravya, G., Rao, C.N., Zyryanov, G.V.
Chalcone synthesis, properties and medicinal applications: a review
(2020) *Environmental Chemistry Letters*, 18 (2), pp. 433-458. Cited 103 times.
<http://springerlink.metapress.com/app/home/journal.asp?wasp=d86tgdwvtg0yvw9gkwp&referrer=parent&backto=browsepublicationsresults,140,541>;
doi: 10.1007/s10311-019-00959-w
View at Publisher

- 38 Pergola, C., Werz, O.
5-Lipoxygenase inhibitors: A review of recent developments and patents
(2010) *Expert Opinion on Therapeutic Patents*, 20 (3), pp. 355-375. Cited 147 times.
doi: 10.1517/13543771003602012
View at Publisher

🔗 Rullah, K.; Drug Discovery And Synthetic Chemistry Research Group, Department Of Pharmaceutical Chemistry, Kulliyah Of Pharmacy, International Islamic University Malaysia, Bandar Indera Mahkota, Kuantan, Pahang, Malaysia;
email:kamalrullah@iium.edu.my
🔗 Aluwi, M.F.F.M.; Faculty Of Industrial Sciences & Technology, Universiti Malaysia Pahang, Lebuhraya Tun Razak, Gambang, Pahang, Malaysia; email:fasihi@ump.edu.my
© Copyright 2022 Elsevier B.V., All rights reserved.

About Scopus

[What is Scopus](#)

[Content coverage](#)

[Scopus blog](#)

[Scopus API](#)

[Privacy matters](#)

Language

[日本語版を表示する](#)

[查看简体中文版本](#)

[查看繁體中文版本](#)

[Просмотр версии на русском языке](#)

Customer Service

[Help](#)

[Tutorials](#)

[Contact us](#)

ELSEVIER

[Terms and conditions](#) ↗ [Privacy policy](#) ↗

Copyright © Elsevier B.V. ↗. All rights reserved. Scopus® is a registered trademark of Elsevier B.V.

We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies ↗.

